Abbott (NYSE:ABT) said today that it has won public reimbursement in Ontario and Quebec for its FreeStyle Libre sensor-based glucose monitoring system — the first of its kind listed by any provincial health plan in Canada.
FreeStyle Libre is designed to monitor glucose levels with a small sensor on the back of the upper arm that can be scanned with a handheld reader or smartphone. It provides real-time glucose readings and allows patients to dose insulin based on the results, eliminating the need for traditional fingersticks, according to Abbott.
Get the full story at our sister site, Drug Delivery Business News.